Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

Chelsea C. Pinnix; Bouthaina S. Dabaja; Sarah A. Milgrom; Grace L. Smith; Zeinab Abou; Loretta Nastoupil; Jorge Romaguera; Francesco Turturro; Nathan Fowler; Luis Fayad; Jason Westin; Sattva Neelapu; Michelle A. Fanale; Maria A. Rodriguez; Frederick Hagemeister; Hun Ju Lee; Yasuhiro Oki; Michael Wang; Felipe Samaniego; Linda Chi; Bita Esmaeli

doi:10.1002/hed.24717

Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

Chelsea C. Pinnix, Bouthaina S. Dabaja, Sarah A. Milgrom, Grace L. Smith, Zeinab Abou, Loretta Nastoupil, Jorge Romaguera, Francesco Turturro, Nathan Fowler, Luis Fayad, Jason Westin, Sattva Neelapu, Michelle A. Fanale, Maria A. Rodriguez, Frederick Hagemeister, Hun Ju Lee, Yasuhiro Oki, Michael Wang, Felipe Samaniego, Linda ChiBita Esmaeli

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

Background: The purpose of this study was to report the response to and toxicity of ultra–low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL). Methods: We conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects. Results: Twenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient. Conclusion: Ultra–low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost.

Original language	English (US)
Pages (from-to)	1095-1100
Number of pages	6
Journal	Head and Neck
Volume	39
Issue number	6
DOIs	https://doi.org/10.1002/hed.24717
State	Published - Jun 2017

Keywords

mantle cell lymphoma
mucosa-associated lymphoid tumor
ocular adnexal lymphoma
orbital lymphoma
radiotherapy

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.24717

Cite this

Pinnix, C. C., Dabaja, B. S., Milgrom, S. A., Smith, G. L., Abou, Z., Nastoupil, L., Romaguera, J., Turturro, F., Fowler, N., Fayad, L., Westin, J., Neelapu, S., Fanale, M. A., Rodriguez, M. A., Hagemeister, F., Lee, H. J., Oki, Y., Wang, M., Samaniego, F., ... Esmaeli, B. (2017). Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head and Neck, 39(6), 1095-1100. https://doi.org/10.1002/hed.24717

Pinnix, CC , Dabaja, BS, Milgrom, SA, Smith, GL, Abou, Z, Nastoupil, L, Romaguera, J, Turturro, F, Fowler, N, Fayad, L , Westin, J , Neelapu, S, Fanale, MA, Rodriguez, MA, Hagemeister, F, Lee, HJ, Oki, Y, Wang, M , Samaniego, F, Chi, L & Esmaeli, B 2017, 'Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma', Head and Neck, vol. 39, no. 6, pp. 1095-1100. https://doi.org/10.1002/hed.24717

@article{0996071fb1ed4b03b667990e7d14865d,

title = "Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma",

abstract = "Background: The purpose of this study was to report the response to and toxicity of ultra–low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL). Methods: We conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects. Results: Twenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient. Conclusion: Ultra–low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost.",

keywords = "mantle cell lymphoma, mucosa-associated lymphoid tumor, ocular adnexal lymphoma, orbital lymphoma, radiotherapy",

author = "Pinnix, {Chelsea C.} and Dabaja, {Bouthaina S.} and Milgrom, {Sarah A.} and Smith, {Grace L.} and Zeinab Abou and Loretta Nastoupil and Jorge Romaguera and Francesco Turturro and Nathan Fowler and Luis Fayad and Jason Westin and Sattva Neelapu and Fanale, {Michelle A.} and Rodriguez, {Maria A.} and Frederick Hagemeister and Lee, {Hun Ju} and Yasuhiro Oki and Michael Wang and Felipe Samaniego and Linda Chi and Bita Esmaeli",

note = "Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2017",

month = jun,

doi = "10.1002/hed.24717",

language = "English (US)",

volume = "39",

pages = "1095--1100",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

AU - Pinnix, Chelsea C.

AU - Dabaja, Bouthaina S.

AU - Milgrom, Sarah A.

AU - Smith, Grace L.

AU - Abou, Zeinab

AU - Nastoupil, Loretta

AU - Romaguera, Jorge

AU - Turturro, Francesco

AU - Fowler, Nathan

AU - Fayad, Luis

AU - Westin, Jason

AU - Neelapu, Sattva

AU - Fanale, Michelle A.

AU - Rodriguez, Maria A.

AU - Hagemeister, Frederick

AU - Lee, Hun Ju

AU - Oki, Yasuhiro

AU - Wang, Michael

AU - Samaniego, Felipe

AU - Chi, Linda

AU - Esmaeli, Bita

PY - 2017/6

Y1 - 2017/6

N2 - Background: The purpose of this study was to report the response to and toxicity of ultra–low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL). Methods: We conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects. Results: Twenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient. Conclusion: Ultra–low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost.

AB - Background: The purpose of this study was to report the response to and toxicity of ultra–low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL). Methods: We conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects. Results: Twenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient. Conclusion: Ultra–low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost.

KW - mantle cell lymphoma

KW - mucosa-associated lymphoid tumor

KW - ocular adnexal lymphoma

KW - orbital lymphoma

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85017144729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017144729&partnerID=8YFLogxK

U2 - 10.1002/hed.24717

DO - 10.1002/hed.24717

M3 - Article

C2 - 28370694

AN - SCOPUS:85017144729

SN - 1043-3074

VL - 39

SP - 1095

EP - 1100

JO - Head and Neck

JF - Head and Neck

IS - 6

ER -

Ultra–low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this